The University of Queensland, Translational Research Institute, University of Queensland Diamantina Institute, Level 6, 37 Kent Street, Woolloongabba, Queensland, 4102, Australia.
School of Biomedical Sciences, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, Queensland, Australia.
J Mol Med (Berl). 2018 Jan;96(1):21-30. doi: 10.1007/s00109-017-1611-8. Epub 2017 Nov 17.
Respiratory allergies represent a significant disease burden worldwide affecting up to 300 million people globally. Medication and avoidance of known triggers do not address the underlying pathology. Traditional immunotherapies for allergy aim to reinstate immune homeostasis but require years of treatment and have poor long-term efficacy. Novel approaches, such as gene-engineered hematopoietic stem cell transplantation, induce profound antigen-specific tolerance in autoimmunity. Recent evidence shows this approach may also have therapeutic utility for allergy. Here, we review the mechanisms of antigen-specific tolerance and the potential of stem cell-mediated gene therapy to induce tolerance in allergic respiratory diseases.
呼吸系统过敏是一种全球性的重大疾病负担,全球多达 3 亿人受其影响。药物治疗和避免已知过敏原并不能解决潜在的病理问题。传统的过敏免疫疗法旨在恢复免疫平衡,但需要多年的治疗且长期疗效不佳。新型方法,如基因工程造血干细胞移植,可诱导自身免疫中的抗原特异性耐受。最近的证据表明,这种方法可能对治疗呼吸系统过敏也具有一定的疗效。在此,我们综述了抗原特异性耐受的机制,以及干细胞介导的基因治疗在诱导过敏性呼吸系统疾病中产生耐受的潜力。